Minimal Residual Disease Assessment in Patients with Colorectal Cancer, the MiRDA-C Study

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byArvind Dasari

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Research Team

Arvind Dasari

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Inclusion Criteria

Age ≥ 18 years.

Histological/cytological confirmation of colorectal adenocarcinoma.

Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.

See 3 more

Treatment Details

Interventions

Minimal Residual Disease Assessment (Biomarker)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Ancillary-correlative (biospecimen collection)Experimental Treatment2 Interventions

Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.